FDA nixes Merck’s shot at getting Januvia cardio safety data onto the label
Merck is not going to get any help from the FDA in marketing its big diabetes drug Januvia.
A $6 billion earner last year, Merck’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
